Advanced Search

The American Journal of Psychiatry, VOL. 163, No. 3

Letter to the Editor | March 01, 2006

Psychosis Related to Ropinirole

ELENA PEREA, M.S.; BRIAN V. ROBBINS, M.D.; BURTON HUTTO, M.D.

Am J Psychiatry 2006;163:547-548. 10.1176/appi.ajp.163.3.547

Article

References

text A A A

To the Editor:

The dopamine receptor agonist ropinirole, an effective initial therapy for mild to moderate Parkinson’s disease, has also been recently indicated for the treatment of restless legs syndrome. Ropinirole has a high affinity for all dopamine D₂ subfamily receptors and shows highest affinity for the D₃ receptor subtype (1). Studies have suggested it has antidepressant qualities in Parkinson’s disease and treatment-resistant depression, and at least two cases of mania have been documented (2, 3). To our knowledge, there have been no reports of cases of psychosis related to the use of ropinirole until now.

Ms. A was a 44-year-old woman with a family history of schizophrenia and a 1-year history of depression who was admitted to the hospital with acute psychotic symptoms, including paranoid delusions, disorganized thoughts, and auditory and visual hallucinations. Her affect was blunted. She had been given a prescription for ropinirole 1 week before admission for restless legs syndrome. Upon admission, the ropinirole was discontinued. Quetiapine and citalopram were prescribed. Within 3 days, Ms. A’s paranoia had improved. Her thought process had become more organized and logical, and her affect had brightened. Her sleep ranged from 7 to 9 hours throughout the hospitalization. She improved steadily each day until her discharge 6 days after admission.

In clinical trials, the dopamine agonist ropinirole has produced hallucinations and confusion rated as mild (4). We provide evidence here that ropinirole may induce or exacerbate severe, acute psychosis in a patient without Parkinson’s disease. This case is not conclusive in part because of the use of quetiapine. However, the rapidity and degree of improvement weigh in favor of a strong role for ropinirole, and the likelihood of such an effect with this medication stands to reason. Given the recognized relationship of dopaminergic function to psychosis, best known through the strong antipsychotic effects of dopamine antagonists, such an effect of exacerbating psychosis by a dopamine agonist seems almost predictable. We suggest that ropinirole, like all other dopaminergic agents, be used with caution in psychotic patients and those vulnerable to psychosis.

References

Willner P: The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997; 12(3 suppl):S7-S14

Singh A, Althoff R, Martineau RJ, Jacobson J: Pramipexole, ropinirole, and mania in Parkinson’s disease (letter). Am J Psychiatry 2005; 162:814–815

Cassano P, Lattanzi L, Fava M, Navari S, Battistini G, Abelli M, Cassano GB: Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005; 50:357–360[PubMed]

Schrag AE, Brooks DJ, Brunt E, Fuell D, Korczyn A, Poewe W, Quinn NP, Rascol O, Stocchi F: The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson’s disease. Clin Neuropharmacol 1998; 21:169–175[PubMed]

Willner P: The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997; 12(3 suppl):S7-S14

Singh A, Althoff R, Martineau RJ, Jacobson J: Pramipexole, ropinirole, and mania in Parkinson’s disease (letter). Am J Psychiatry 2005; 162:814–815

Cassano P, Lattanzi L, Fava M, Navari S, Battistini G, Abelli M, Cassano GB: Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005; 50:357–360[PubMed]

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.

Submit a Comments

Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of JBJS editorial staff.

* = Required Field

Comment Author(s)*(if multiple authors, separate names by comma)

Example: John Doe

Affiliation & Institution*

Comment Title*

Comment*

Cancel

Print
PDF
E-mail

Recipient(s) will receive an email with a link (good for 72 hours) to 'Psychosis Related to Ropinirole' and do not need to have American Journal of Psychiatry account to access the content.
Your Name:*
Example: John Doe

Email Address:* CC Me:
Enter your valid email address. Example: jdoe@example.com

Recipient's Email Address:*
Separate multiple email address with semi-colons (up to 5).

Subject:* 's American Journal of Psychiatry: 'Psychosis Related to Ropinirole'
Subject for your email.

Message:
(Optional, message will truncate at 1000 characters)

Processing your request... Please Wait...

Copyright © in the material you requested is held by The American Psychiatric Association (unless otherwise noted). This email ability is provided as a courtesy, and by using it you agree that you are requesting the material solely for personal, non-commercial use, and that it is subject to The American Psychiatric Association's Terms of Use. The information provided in order to email this topic will not be used to send unsolicited email, nor will it be furnished to third parties. Please refer to The American Psychiatric Association's Privacy Policy for further information.

Copyright © American Psychiatric Association. All rights reserved.
Share
Get Citation

ELENA PEREA, BRIAN V. ROBBINS, BURTON HUTTO; Psychosis Related to Ropinirole. American Journal of Psychiatry. 2006 Mar;163(3):547-548.

Download citation file:

RIS (Zotero)

EndNote

BibTex

Medlars

ProCite

RefWorks

Reference Manager

Copyright © American Psychiatric Association. All rights reserved.
Reprints